ClinicalTrials.gg

Gilead Sciences clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 738 studies whose lead sponsor is Gilead Sciences or one of 2 companies grouped under it. 32 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Gilead Sciences with GlaxoSmithKline and Johnson & Johnson →

Pipeline: 32 programs

Each counted once: 32 with a study Gilead Sciences leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 15 with the most live studies.

Program
anitocabtagene autoleucelPhase 3 · 6 live · Multiple Myeloma · primary completion Dec 2026☆ Track
domvanalimabPhase 3 · 5 live · Carcinoma, Non-Small-Cell Lung · primary completion Mar 2027☆ Track
seladelparPhase 3 · 3 live · Liver Cirrhosis, Biliary · primary completion Nov 2028☆ Track
axicabtagene ciloleucelPhase 3 · 3 live · Lymphoma, B-Cell · primary completion Oct 2030☆ Track
GS-3242Phase 3 · 3 live · primary completion Aug 2027☆ Track

10 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Gilead Sciences’ own registered studies; Gilead Sciences’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Gilead Sciences’ studies test, most open studies first — 131 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 131; every drug is on its own page, and each page lists its sponsors.

Coming up

19 of Gilead Sciences’ studies under way reach primary completion within a year, 3 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 4D
  3. 1J’27
  4. 2F
  5. 4M
  6. A
  7. 1M
  8. 2J
  9. 1J
  10. 2A
  11. S
  12. O
  13. 1N

The 12 nearest

Show 7 more

Add all 19 to your calendar (.ics) → With an account.

All 738 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now324%Recruiting 26 · Not yet recruiting 4 · Enrolling by invitation 2
  • Under way, not recruiting557%
  • Completed48365%
  • Stopped early14820%Terminated 132 · Withdrawn 16
  • Status unknown or other203%Approved for marketing 10 · Status unknown 7 · Available 2 · No longer available 1

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 7715
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 1626

By the year each study started; 80 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Gilead Sciences.

  • Gilead Sciences
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    692 studies
  • Kite, A Gilead Company
    Acquired — became part of Gilead Sciences, Oct 3, 2017 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    40 studies →
  • Pharmasset
    Acquired — became part of Gilead Sciences, Jan 12, 2012 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →

Focus areas

Conditions Gilead Sciences leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 25 areas

Studies

Recruiting first, then most recently updated. Showing 50 of 738. Browse all 738 →